CASI Pharmaceuticals Schedules Business Update Amid Legal Proceedings

CASI Pharmaceuticals ( (CASI) ) just unveiled an announcement.

On May 19, 2025, CASI Pharmaceuticals announced a live conference call and webcast scheduled for May 21, 2025, to provide a business and clinical update. This announcement highlights CASI’s ongoing efforts to strengthen its market position and communicate its strategic and operational plans to stakeholders. The company is involved in legal proceedings related to certain pipeline products, including EVOMELA® and CNCT-19, which could impact its operations and market strategy.

The most recent analyst rating on (CASI) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.

Spark’s Take on CASI Stock

According to Spark, TipRanks’ AI Analyst, CASI is a Neutral.

CASI Pharmaceuticals faces substantial financial difficulties, with declining revenues and increasing losses, reflected in a low financial performance score. The technical analysis indicates a bearish trend, and the valuation is unattractive due to negative earnings and lack of dividends. These factors contribute to a low overall stock score, highlighting the need for significant improvements in operational efficiency and revenue growth.

To see Spark’s full report on CASI stock, click here.

More about CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing and commercializing innovative therapeutics and pharmaceutical products. The company operates primarily in China, the United States, and globally, with a focus on hematology oncology therapeutics, organ transplant rejection, autoimmune diseases, and other unmet medical needs. CASI aims to become a leader in the Greater China market by leveraging its regulatory and commercial expertise in China and its global drug development capabilities.

Average Trading Volume: 9,296

Technical Sentiment Signal: Sell

Current Market Cap: $29.55M

Learn more about CASI stock on TipRanks’ Stock Analysis page.